Hetero Ring Containing Patents (Class 534/551)
  • Patent number: 9822266
    Abstract: An azo pigment is provided which can be used as a coloring agent, etc. for use in paints, plastics, synthetic fibers, printing inks, and writing materials or for image recording or image displaying and which has performance of exhibiting high near infrared reflection/transparency, particularly when used as a heat-shielding paint, even in the case where the pigment has a dark color, and as a result, colored articles having the above-described properties are provided, and furthermore an article that is also useful as a printing ink in the security field is provided particularly when the pigment has a dark or black color. Specifically, an azo pigment is provided which is obtained through coupling reaction between a particular azo component and a particular coupling component, which has a plurality of chromophores of an azomethine group and of an azo group within a molecule, and in which the diazo component is a diazotized product of 3-(4-aminophenylimino)-1-oxo-4,5,6,7-tetrachroloisoindoline.
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: November 21, 2017
    Assignee: DAINICHISEIKA COLOR & CHEMICALS MFG. CO., LTD.
    Inventors: Hisao Okamoto, Hideki Ito, Hiromitsu Yanagimoto
  • Patent number: 9704997
    Abstract: The present polymeric materials can be patterned with relatively low photo-exposure energies and are thermally stable, mechanically robust, resist water penetration, and show good adhesion to metal oxides, metals, metal alloys, as well as organic materials. In addition, these polymeric materials can be solution-processed (e.g., by spin-coating), and can exhibit good chemical (e.g., solvent and etchant) resistance in the cured form.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: July 11, 2017
    Assignee: Flexterra, Inc.
    Inventors: Shaofeng Lu, Daniel Batzel, Chun Huang, Minhuei Wang, Meko McCray, Yu Xia, Antonio Facchetti
  • Patent number: 9190493
    Abstract: The present polymeric materials can be patterned with relatively low photo-exposure energies and are thermally stable, mechanically robust, resist water penetration, and show good adhesion to metal oxides, metals, metal alloys, as well as organic materials. In addition, these polymeric materials can be solution-processed (e.g., by spin-coating), and can exhibit good chemical (e.g., solvent and etchant) resistance in the cured form.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: November 17, 2015
    Assignee: Polyera Corporation
    Inventors: Shaofeng Lu, Daniel Batzel, Chun Huang, Minhuei Wang, Meko McCray, Yu Xia, Antonio Facchetti
  • Publication number: 20150141378
    Abstract: Described herein are nitroxyl progenitor compounds, and compositions including, and methods or generating, the compounds thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions.
    Type: Application
    Filed: September 22, 2014
    Publication date: May 21, 2015
    Inventors: John P. Toscano, Christopher M. Pavlos, Preeya Kapur Boppana
  • Publication number: 20150011513
    Abstract: A triazole bridged flavonoid dimer compound library was efficiently constructed via the cycloaddition reaction of a series of flavonoid-containing azides (Az 1-15) and alkynes (Ac 1-17). These triazole bridged flavonoid dimers and their precursor alkyne- and azide-containing flavonoids were screened for their ability to modulate multidrug resistance (MDR) in P-gp-overexpressed cell line (LCC6MDR), MRP1-overexpressed cell line (2008/MRP1) and BCRP-overexpressed cell line (HEK293/R2 and MCF7-MX100). Generally, they displayed very promising MDR reversal activity against P-gp-, MRP1- and BCRP-mediated drug resistance. Moreover, they showed different levels of selectivity for various transporters. Overall, they can be divided into mono-selective, dual-selective and multi-selective modulators for the P-gp, MRP1 and BCRP transporters.
    Type: Application
    Filed: March 1, 2013
    Publication date: January 8, 2015
    Inventors: Larry Ming Cheung Chow, Tak Hang Chan, Kin Fai Chan, Iris Lai King Wong, Man Chun Law
  • Publication number: 20140221316
    Abstract: This disclosure relates to novel compounds containing an H2S releasing moiety and a nitric oxide (NO) releasing moiety covalently linked with a core (e.g., a salicylic acid moiety) and the use of such compounds in treating inflammatory diseases, including cancers. Therapeutic potency of these compounds is significantly higher than NSAIDs containing a H2S-releasing moiety alone (HS-NSAIDs) and NSAID containing a NO-releasing moiety alone (NO-NSAIDs). The compounds, in addition, exhibit reduced side effect, e.g., reduced stomach ulcers, upon administration.
    Type: Application
    Filed: August 15, 2012
    Publication date: August 7, 2014
    Applicant: RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK
    Inventors: Khosrow Kashfi, Ravinder Kodela
  • Publication number: 20140135295
    Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt of the compound. Also described are pharmaceutical formulations thereof and methods of using the same.
    Type: Application
    Filed: November 8, 2013
    Publication date: May 15, 2014
    Applicant: IRONWOOD PHARMACEUTICALS
    Inventors: Jeffrey Segal, Nisha Perez, Timothy Claude Barden
  • Publication number: 20140093869
    Abstract: This invention provides novel azido linkers for deoxynucleotide analogues having a detectable marker attached thereto.
    Type: Application
    Filed: July 25, 2013
    Publication date: April 3, 2014
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Jingyue Ju, Huanyan Cao, Zengmin Li, Qinglin Meng, Jia Guo, Shenglong Zhang
  • Publication number: 20140088048
    Abstract: A compound having the structure or a pharmaceutically acceptable salt thereof, wherein R6 is hydrogen, —OH, —C1-6alkyl, —OC1-6alkyl, aryl, or halogen, or together with R7, forms an oxo group, or together with R7 and the atom to which they are attached, form a 5-7-membered carbocycle ring or a 5-7-membered heterocyclic ring having 1, 2, or 3 heteroatoms, wherein alkyl and aryl are unsubstituted or independently mono-, di-, or tri-substituted with R14; R7 is hydrogen, C1-6alkyl, —CF3, aryl, —O-aryl, —O—C1-6alkyl, —C(O)OC1-6alkyl, —C(R15R16)OH, a 5-7-membered heteroaryl having 1, 2, 3 or 4 nitrogen atoms, or halogen, or together with R6, forms an oxo group, or together with R6 and the atom to which they are attached, form a 5-7-membered carbocycle ring or a 5-7-membered heterocyclic ring having 1, 2, or 3 heteroatoms wherein alkyl, aryl and heteroaryl are unsubstituted or independently mono-, di- or tri-substituted with R14; R12 is hydrogen, C1-6alkyl, or —(CH2)1-2OH, or together with R13 and the nitr
    Type: Application
    Filed: April 27, 2012
    Publication date: March 27, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Michael Man-Chu Lo, Lin Yan
  • Publication number: 20140066598
    Abstract: Provided herein are modified amino acids comprising an azido group, polypeptides, antibodies and conjugates comprising the modified amino acids, and methods of producing the polypeptides, antibodies and conjugates comprising the modified amino acids. The polypeptides, antibodies and conjugates are useful in methods of treatment and prevention, methods of detection and methods of diagnosis.
    Type: Application
    Filed: August 30, 2013
    Publication date: March 6, 2014
    Applicant: Sutro Biopharma, Inc.
    Inventors: Ryan Stafford, Christopher D. Thanos, Wenjin Yang
  • Publication number: 20140005149
    Abstract: Triazene-substituted diphenyl derivatives are suitable as chemotherapeutic agents for treating carcinomas in humans and animals.
    Type: Application
    Filed: July 15, 2011
    Publication date: January 2, 2014
    Inventor: Heinz Förster
  • Publication number: 20140005370
    Abstract: Disclosed herein is a compound having Formula I: or a salt thereof, in which R1, R2 and R3 are as defined herein. Also disclosed are processes to prepare compounds of Formula I and use of compounds of Formula I to prepare stable glassy phases.
    Type: Application
    Filed: December 14, 2012
    Publication date: January 2, 2014
    Applicant: Her Majesty the Queen in right of Canada as represented by the Minister of National Defence
    Inventor: Her Majesty the Queen in right of Canada as represented by the Minister of National Defence
  • Publication number: 20130061773
    Abstract: Modified pigments including an organic group containing a 5-membered heteroaromatic ring, as well as related compositions, articles, and methods, are disclosed. The diazonium salts containing a 5-membered heteroaromat is ring exhibit enhanced activity in modifying pigments, thereby resulting in modified pigments with a higher treatment level and improved dispersibility in an ink composition.
    Type: Application
    Filed: May 13, 2011
    Publication date: March 14, 2013
    Applicant: CABOT CORPORATION
    Inventor: Alexander I. Shakhnovich
  • Publication number: 20130053352
    Abstract: A compound having the structure or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen, —OH, —O—C1-6 alkyl, ?O, or halogen; R2 is hydrogen, C(O)OR8, C6H5C(O)OR8, (CH2)1-2OH, CR9R10OH, C(O)O(CH2)0-2 aryl, C(O)NR9R10, C(O)SO2NR9R10, C6H5OR9, W—C(O)OR8, W—OR9, Y, or P(O)(OR9)(ORlO); R3 is hydrogen or —C1-6 alkyl; R4 is hydrogen, —OH or —C(O)OR9; R5 is hydrogen or deuterium; R6 and R7 are independently —C1-6 alkyl, fluoro-substituted —C1-6 alkyl, deutero-substituted —C1-6 alkyl or —(CH2)1-2R11, wherein any carbon atom of the fluoro-substituted —C1-6 alkyl is mono- or di-substituted with fluoro, and any carbon atom of the deutero-substituted —C1-6 alkyl is mono- or di-substituted with fluoro; R8, in each instance in which it occurs, is independently hydrogen, —C1-6 alkyl, or —(CH2)2N+(CH3)3; R9 and R10, in each instance in which they occur, are independently —C1-6 alkyl; R11 is —OH, —O—C1-6 alkyl, -0CD3, —OC(O)OC1-6 alkyl, —NH2, —C6H5, —N3, or W; W is an unsubslituted 5- or 6-raembered heteroaryl ri
    Type: Application
    Filed: February 10, 2011
    Publication date: February 28, 2013
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Amjad Ali, Michael Man-Chu Lo, Edward Metzger, Lin Yan
  • Patent number: 8361994
    Abstract: A compound having the structure useful for treating hypertension, Pulmonary Arterial Hypertension (PAH), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: January 29, 2013
    Assignee: Merck Sharp & Dohme Corp
    Inventors: Amjad Ali, Michael Man-Chu Lo, Zhiqiang Guo, Brent Whitehead, Timothy J. Henderson, Lin Yan, Shrenik K. Shah
  • Patent number: 8354394
    Abstract: A compound having the structure (I) wherein R is selected from the group consisting of 1) and 2), or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: January 15, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Christopher Franklin, Ravi Nargund, Michael Man-Chu Lo, Lin Yan, Pei Huo
  • Publication number: 20120232039
    Abstract: A compound having the structure useful for treating hypertension, Pulmonary Arterial Hypertension (PAH), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy.
    Type: Application
    Filed: March 5, 2012
    Publication date: September 13, 2012
    Inventors: Amjad ALI, Michael Man-Chu Lo, Brent Whitehead, Shrenik K. Shah, Lin Yan, Timothy J. Henderson, Zack Zhiqiang Guo
  • Patent number: 8258119
    Abstract: The present invention discloses triazene analogs of the general formula (I) and formula (II), their tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts thereof for the metastatic malignant melanoma and other cancers including but not limited to lymphomas, sarcomas, carcinomas, and gliomas. The invention further discloses a process for the preparation of the above said triazene analogs of formula (I) and formula (II), and their pharmaceutically acceptable compositions.
    Type: Grant
    Filed: September 15, 2009
    Date of Patent: September 4, 2012
    Assignee: Kasina Laila Innova Pharmaceuticals
    Inventors: Ganga Raju Gokaraju, Sudhakar Kasina, Rama Raju Gokaraju, Trimurtulu Golakoti, Venkateswarlu Somepalli, Sengupta Krishanu, Kiran Bhupathiraju
  • Publication number: 20120145290
    Abstract: Embodiments of materials suitable for use as a replacement for Tetrazene and methods of preparing such materials are described. In one embodiment, the material comprises MTX-1, as well as simple salts or complexes derived therefrom. The methods of preparing such materials include combining Tetrazene and an acid to form a suspension, where the acid is nitric acid, sulfuric acid, perchloric acid, or hydrochloric acid. A nitrite salt may be added to the suspension, where the nitrite salt is sodium nitrite, lithium nitrite, potassium nitrite, an aqueous solution of sodium nitrite, an aqueous solution of lithium nitrite, or an aqueous solution of potassium nitrite. In some embodiments, the suspension is stirred until the suspension has a white appearance.
    Type: Application
    Filed: April 21, 2011
    Publication date: June 14, 2012
    Inventors: JOHN W. FRONABARGER, MICHAEL D. WILLIAMS
  • Patent number: 8143237
    Abstract: Selenopheno triazene analogs, their compositions, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts and mixtures thereof are useful for the treatment of metastatic malignant melanoma and other cancers. The selenopheno triazene analogs have the general formulae (I) or (II): wherein the substituents R1, R2, R3, R6, and R7 are as described in the specification. Other cancers include which may be treated with these compounds include, but are not limited to, malignant melanoma, leukemia, lymphomas (Hodgkins and non-Hodgkins), sarcomas (Ewing's sarcoma), brain tumors, central nervous system (CNS) metastases, gliomas, carcinomas such as breast cancer, prostate cancer, lung cancer (small cell and non-small cell), colon cancer, pancreatic cancer, Head and Neck cancers and oropharyngeal squamous cell carcinoma.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: March 27, 2012
    Assignee: Kasina Laila Innova Pharmaceuticals Private Limited
    Inventors: Ganga Raju Gokaraju, Sudhakar Kasina, Rama Raju Gokaraju, Venkata Kanaka Ranga Raju Gokaraju, Venkateswarlu Somepalli, Trimurtulu Golakoti, Kiran Bhupathiraju, Sengupta Krishanu, Venkata Krishna Raju Alluri
  • Publication number: 20120041093
    Abstract: The invention relates to the use of triazenes of formula (I) wherein Q is a direct bond or a bivalent radical —(CR8R9)—, Z1 is —O—, —NR10—, —CH2—, —(CR11R12)— or —C(?O)— and R1 to R12 are optionally substituted hydrocarbon residues, as precursors for radicals useful in reactions triggered by free radicals, such as polymerization of unsaturated monomers and degradation of polyolefins. Most of the triazenes of formula (I) are novel and claimed, too, as well as the preparation of triazenes of formula (I) and polymerisable compositions comprising them.
    Type: Application
    Filed: March 26, 2010
    Publication date: February 16, 2012
    Applicant: BASF SE
    Inventors: Peter Nesvadba, Lucienne Bugnon Folger, Jean-Luc Birbaum, Marc Faller, Antoine Carroy
  • Patent number: 8106089
    Abstract: The invention relates to a compound represented by general formula (I) wherein Z represents N, O or S, and A represents a CH group, a nitrogen atom or an NL+ group wherein L represents a straight-chained or branched C1-C12 alkyl group. The invention also relates to a method for the preparation thereof and the use thereof as an antimitotic.
    Type: Grant
    Filed: May 13, 2005
    Date of Patent: January 31, 2012
    Assignees: Centre National de la Recherche, Universite de Rennes 1
    Inventors: Yannick Arlot, Bénédicte Martin, Jean-Guy Delcros, Gilles Alcaraz, Olivier Paulus
  • Patent number: 8106034
    Abstract: A compound having the structure wherein R is an angiotensin receptor blocking group Y is —(CR1R20)1-7R5, or —C(O)(CR1R20)1-7R5; R1 and R20 are independently selected from the group consisting of hydrogen or C1-4 alkyl; R5 is —O—N?N(O)—NR3R4; and R3 and R4 are independently selected from the group consisting of —CH2CH2OH, —CH2CH2OCH3, —C1-4 alkyl, unsubstituted or substituted C1-6 alkenyl, unsubstituted or substituted morpholino, amino, unsubstituted or substituted benzyl, unsubstituted or substituted phenyl, unsubstituted or substituted arylC1-4 alkyl, or R3 and R4 together with the nitrogen atom to which they are attached, form a ring selected from the group consisting of or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof, which is useful for treating hypertension.
    Type: Grant
    Filed: January 29, 2009
    Date of Patent: January 31, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Michael Man-Chu Lo
  • Publication number: 20110319603
    Abstract: A method for fluorescently labeling a protein is provided that can also be used for labeling a biomolecule (a protein) in vivo with fluorescence.
    Type: Application
    Filed: March 10, 2010
    Publication date: December 29, 2011
    Applicant: OSAKA UNIVERSITY
    Inventors: Kazuya Kikuchi, Yuichirou Hori, Hideki Ueno
  • Publication number: 20110021762
    Abstract: A process is provided for the synthesis of 4,5-diamino cyclohexene carboxylate ester (1): or a pharmaceutically acceptable salt thereof. R1-R3 are a silyl-, an aliphatic, alicyclic, aromatic, arylaliphatic, or an arylalicyclic group. R4, R11 and R12 are H, a silyl-group, an aliphatic, alicyclic, aromatic, arylaliphatic, or an arylalicyclic group. 3,4-Dihydropyran compound (9): with R5 and R6 being suitable protecting groups, is reacted to form aldehyde (4): which is oxidized and converted to N-substituted carbamate (3): with R7 being a suitable protecting group. (3) is, via oxazolinidone (13): converted to azido carboxylate ester (2): and then to 4,5-diamino cyclohexene carboxylate ester (1).
    Type: Application
    Filed: December 10, 2008
    Publication date: January 27, 2011
    Applicant: NANYANG TECHNOLOGICAL UNIVERSITY
    Inventors: Xuewei Liu, Jimei Ma
  • Publication number: 20100298277
    Abstract: A compound having the structure wherein R is an angiotensin receptor blocking group Y is —(CR1R20)1-7R5, or —C(O)(CR1R20)1-7R5; R1 and R20 are independently selected from the group consisting of hydrogen or C1-4 alkyl; R5 is —O—N?N(O)—NR3R4; and R3 and R4 are independently selected from the group consisting of —CH2CH2OH, —CH2CH2OCH3, —C1-4 alkyl, unsubstituted or substituted C1-6 alkenyl, unsubstituted or substituted morpholino, amino, unsubstituted or substituted benzyl, unsubstituted or substituted phenyl, unsubstituted or substituted arylC1-4 alkyl, or R3 and R4 together with the nitrogen atom to which they are attached, form a ring selected from the group consisting of or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof, which is useful for treating hypertension.
    Type: Application
    Filed: January 29, 2009
    Publication date: November 25, 2010
    Inventors: Amjad Ali, Michael Man-Chu Lo
  • Publication number: 20100292192
    Abstract: A compound having the structure wherein R is an angiotensin receptor antagonist active group, Y is selected from the group consisting of and 2) —C(R1H)OC(O)X((CR12R13)—(CHR10)m—(CH2)n—Zp—(CH2)q—(CHR11)r—(CR16R17))—R5; Z is —O— or —(CR14R15)_; m, n, p, q, and r are independently selected from the group consisting of 0 and 1; X is —O— or —(CR18R19)—; R1 is selected from the group consisting of hydrogen, C1-4 alkyl, aryl and C1-4 alkylaryl; R5 is —O—N?N(O)—NR3R4; or a pharmaceutically acceptable salt or hydrate thereof, which is useful for treating hypertension.
    Type: Application
    Filed: January 8, 2009
    Publication date: November 18, 2010
    Inventors: Amjad Ali, Michael Man-Chu Lo, Christopher Franklin, Brent R. Whitehead
  • Patent number: 7824449
    Abstract: A hair dye composition containing a triazene dissociative direct dye represented by general formula (1): A-N?N—NH-B (1) wherein A and B are each a monocyclic or a bicyclic aromatic heterocyclic group that may have a substituent or a monocyclic or a bicyclic aryl group that may have a substituent and contain none of a carboxy group, a sulfo group and a quaternary ammonium group; and A and B each bind to a triazene-1,3-diyl group represented by —N?N—NH— via a carbon atom within A and B each. A and B may be the same or different.
    Type: Grant
    Filed: April 25, 2008
    Date of Patent: November 2, 2010
    Assignees: Kao Corporation, FUJIFILM Corporation
    Inventors: Miyuki Hayama, Osamu Takiguchi, Yoshimasa Tate, Masaaki Tsukase
  • Publication number: 20100272678
    Abstract: Selenopheno triazene analogs, their compositions, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts and mixtures thereof are useful for the treatment of metastatic malignant melanoma and other cancers. The selenopheno triazene analogs have the general formulae (I) or (II): wherein the substituents R1, R2, R3, R6, and R7 are as described in the specification. Other cancers include which may be treated with these compounds include, but are not limited to, malignant melanoma, leukemia, lymphomas (Hodgkins and non-Hodgkins), sarcomas (Ewing's sarcoma), brain tumors, central nervous system (CNS) metastases, gliomas, carcinomas such as breast cancer, prostate cancer, lung cancer (small cell and non-small cell), colon cancer, pancreatic cancer, Head and Neck cancers and oropharyngeal squamous cell carcinoma.
    Type: Application
    Filed: April 26, 2010
    Publication date: October 28, 2010
    Applicant: KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITE
    Inventors: Ganga Raju GOKARAJU, Sudhakar Kasina, Rama Raju Gokaraju, Venkata Kanaka Ranga Raju Gokaraju, Venkateswarlu Somepalli, Trimurtulu Golakoti, Kiran Bhupathiraju, Sengupta Krishanu, Venkata Krishna Raju Alluri
  • Publication number: 20100240618
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: September 8, 2009
    Publication date: September 23, 2010
    Applicant: ChemoCentryx, Inc.
    Inventors: Andrew M.K. Pennell, James B. Aggen, J.J. Kim Wright, Subhabrata Sen, Brian E. McMaster, Daniel Joseph Dairaghi, Wei Chen, Penglie Zhang
  • Publication number: 20100203647
    Abstract: Methods and kits for detecting acylated proteins produced by cells that have been cultured or by cells within an organism are provided. Also provided are methods and kits for detecting acylated proteins produced by cells where affinity purification tags are that facilitate detection are used. Compounds useful for the detection of acylated proteins are also provided.
    Type: Application
    Filed: November 20, 2009
    Publication date: August 12, 2010
    Applicant: THE ROCKEFELLER UNIVERSITY
    Inventors: HOWARD C. HANG, GUILLAUME CHARRON, JOHN P. WILSON, ANURADHA RAGHAVAN, MINGZI ZHANG, YU-YING YANG, KAVITA RANGAN, LUN K. TSOU, JACOB YOUNT
  • Publication number: 20100183726
    Abstract: A uniform microfluidized nanoemulsion is disclosed containing an anti-cancer agent, such as dacarbazine. The microfluidized nanoemulsion improves the combination's cell membrane permeability by at least four-fold over conventional nanoemulsion compositions, which significantly increases the intracellular concentration of anti-cancer agents. As a nanoemulsion, dacarbazine has a greater anti-cancer efficacy than when applied as a free solution.
    Type: Application
    Filed: August 2, 2007
    Publication date: July 22, 2010
    Inventors: Robert Nicolosi, Jean-Bosco Tagne
  • Publication number: 20100115710
    Abstract: A hair dye composition containing a triazene dissociative direct dye represented by general formula (1): A—N=N—NH—B (1) wherein A and B are each a monocyclic or a bicyclic aromatic heterocyclic group that may have a substituent or a monocyclic or a bicyclic aryl group that may have a substituent and contain none of a carboxy group, a sulfo group and a quaternary ammonium group; and A and B each bind to a triazene-1,3-diyl group represented by —N=N—NH— via a carbon atom within A and B each. A and B may be the same or different.
    Type: Application
    Filed: April 25, 2008
    Publication date: May 13, 2010
    Applicants: Kao Corporation, FujiFilm Corporation
    Inventors: Miyuki Hayama, Osamu Takiguchi, Yoshimasa Tate, Masaaki Tsukase
  • Publication number: 20100068178
    Abstract: The present invention discloses triazene analogs of the general formula (I) and formula (II), their tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts thereof for the metastatic malignant melanoma and other cancers including but not limited to lymphomas, sarcomas, carcinomas, and gliomas. The invention further discloses a process for the preparation of the above said triazene analogs of formula (I) and formula (II), and their pharmaceutically acceptable compositions.
    Type: Application
    Filed: September 15, 2009
    Publication date: March 18, 2010
    Applicant: LAILA NUTRACEUTICALS
    Inventors: Ganga Raju Gokaraju, Sudhakar Kasina, Rama Raju Gokaraju, Trimurtulu Golakoti, Venkateswarlu Somepalli, Sengupta Krishanu, Kiran Bhupathiraju
  • Patent number: 7638609
    Abstract: A compound of Formula (1) or salt thereof: wherein: A is optionally substituted phenyl or naphthyl; B is optionally substituted phenylene or naphthylene; n is 0 or 1; and D is a pyrazolyl group, with the proviso that when A is an optionally substituted phenyl group and B is a phenylene group of Formula T, wherein Ra is OH or a C1-4-alkoxy group; and Rb is H or a C1-4-alkyl group, hydroxy group, C1-4-alkoxy group, C1-3-dialkyamino group or a group of the formula NHCORc (wherein Rc is C1-3-alkyl or an amino group); and * shows the point of attachment to the azo linkages on B in Formula (1); A is free from nitro groups. Also, claimed are compounds, compositions and ink-jet cartridges for use in an ink-jet printer and substrate printed with an ink-jet printer.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: December 29, 2009
    Assignee: Fujifilm Imaging Colorants Limited
    Inventors: Prahalad Manibhai Mistry, Roy Bradbury
  • Publication number: 20090318380
    Abstract: Embodiments of the invention are to compounds, methods, and compositions for use in the treatment of viral infections. More specifically embodiments of the invention are 2?,4?-substituted nucleoside compounds useful for the treatment of viral infections, such as HIV, HCV, and HBV infections.
    Type: Application
    Filed: November 14, 2008
    Publication date: December 24, 2009
    Applicant: PHARMASSET, INC.
    Inventors: MICHAEL JOSEPH SOFIA, JINFA DU
  • Publication number: 20090186859
    Abstract: Disclosed are compounds that release nitric oxide, e.g., a compound of Formula (I) wherein R1-10, X, and n are as described herein, which are NSAID derivatives comprising a diazeniumdiolate moiety N2O2?. The compounds are chemopreventive agents with gastric-sparing, analgesic, cardioprotective, and/or anti-inflammatory properties. Also disclosed is a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable carrier. Also disclosed is a method of preventing or treating cancer or treating inflammation or an inflammation-related condition in a mammal comprising administering an effective amount of a compound of the invention to the mammal.
    Type: Application
    Filed: April 24, 2007
    Publication date: July 23, 2009
    Applicants: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SEC., DEPT. OF HEALTH AND HUMAN SERVICES, The Governors of the University of Alberta
    Inventors: Carlos A. Velázquez, Joseph E. Saavedra, Larry Keefer, Brett Showalter, Edward E. Knaus
  • Publication number: 20090068248
    Abstract: The present invention provides compound of the formula (I): in which at least two of R1, R2, R3, R4, R5, and R6 are N2O2M and related compounds, substrates, compositions, and methods of using such compounds and compositions to treat biological disorders in which a polyphasic release of nitric oxide would be beneficial.
    Type: Application
    Filed: November 11, 2008
    Publication date: March 12, 2009
    Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HE
    Inventors: David J. Waterhouse, Preeya Kapur, Larry K. Keefer, Joseph A. Hrabie, Frank De Rosa
  • Patent number: 7399434
    Abstract: An article of manufacture marked with compositions comprising rare earth metal compounds which, due to their luminescence when irradiated with UV light, are suitable in particular for the marking of security-relevant items, such as documents or data carriers.
    Type: Grant
    Filed: November 8, 2006
    Date of Patent: July 15, 2008
    Assignee: Honeywell International Inc
    Inventors: Thomas Potrawa, Joachim Schulz
  • Patent number: 7198732
    Abstract: Rare earth metal compounds are described which, due to their luminescence when irradiated with UV light, are suitable in particular for the marking of security-relevant items, such as documents or data carriers.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: April 3, 2007
    Assignee: Honeywell International Inc.
    Inventors: Thomas Potrawa, Joachim Schulz
  • Patent number: 7122529
    Abstract: Chemical compounds which release nitric oxide in a controlled manner upon photolysis with light are provided. These compounds are O2-benzyl, O2-naphthylmethyl and O2-naphthylallyl substituted diazeniumdiolates. Also provided are methods of preparing these novel compounds in high chemical yields as well as methods of using these compounds.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: October 17, 2006
    Assignee: The Johns Hopkins University
    Inventors: Patrick H. Ruane, John P. Toscano
  • Patent number: 6972334
    Abstract: A novel bathophenanthroline compound of the general formula [I] or [II] is provided wherein R1 and R2 may be the same or different and independently represent a linear, branched or cyclic, saturated or unsaturated hydrocarbon group, or a substituted or unsubstituted, saturated or unsaturated hydrocarbon group provided that at least one of R1 and R2 has at least two carbon atoms, and wherein Ar1 and Ar2 may be the same or different and independently represent a substituted or unsubstituted aryl group. A process for preparing the compound is also provided wherein bathophenanthroline and an organolithium compound are subjected to nucleophilic substitution reaction to obtain the compound of the above formula [I] or [II].
    Type: Grant
    Filed: November 2, 2000
    Date of Patent: December 6, 2005
    Assignee: Sony Corporation
    Inventors: Tetsuo Shibanuma, Yasunori Kijima, Nobutoshi Asai, Shinichiro Tamura
  • Patent number: 6911433
    Abstract: Provided are O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates (O2-glycosylated diazeniumdiolates) having the formula: in which R is a saccharide, which is attached to the O2 of the compound by the anomeric carbon of a pyranose ring or a furanose ring.
    Type: Grant
    Filed: January 7, 2003
    Date of Patent: June 28, 2005
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Joseph E. Saavedra, Larry K. Keefer, Aloka Srinivasan, Christian Bogdan, William G. Rice, Xinhua Ji
  • Publication number: 20040081959
    Abstract: Oligonucleotide probes containing two labels are provided and are useful in hybridization assays. The probes can also contain a minor groove binding group.
    Type: Application
    Filed: March 29, 2002
    Publication date: April 29, 2004
    Applicant: Epoch Biosciences, Inc.
    Inventors: Michael W. Reed, Eugeny Alexander Lukhtanov, Alexander A. Gall, Robert O. Dempcy, Nicolaas M.J. Vermeulen
  • Publication number: 20040034023
    Abstract: The invention concerns the use of aromatic compounds capable of binding with G-quadruplex structures to produce medicines with anti-telomerase effect. Said compounds correspond to formula (I) wherein: R1, R2 and R3, identical or different, represent a hydrogen atom, or a —CH2—NH—(CH2)n—X group, wherein n is an integer from 2 to 4, and X is selected among —NH2—, —N(CH3)2 radicals, a heterocyclic radical such as piperidyl, imidazolyl, morpholinyl radical, or an indole-type condensed heterocyclic radical, —Z represents CH or N, each compound comprising two nitrogen atoms in the Z positions. The invention is useful for producing anticancer medicines.
    Type: Application
    Filed: July 15, 2003
    Publication date: February 19, 2004
    Inventors: Jean-Louis Mergny, Laurent Lacroix, Marie-Paule Teulade-Fichou, Jean-Pierre Vigneron, Jean-Marie Lehn, Claude Helene
  • Publication number: 20030175616
    Abstract: The invention relates to a write-once optical data carrier in which organic and/or inorganic light-absorbing compounds are used as the information layer, especially for high-density optical data carriers which function with a blue laser in the wavelength range of 360-460 nm. The invention also relates to the application of the above-mentioned light-absorbing compound to a suitable substrate (especially polycarbonate), e.g. by spin coating.
    Type: Application
    Filed: October 2, 2002
    Publication date: September 18, 2003
    Inventors: Horst Berneth, Friedrich-Karl Bruder, Karin Hasenruck
  • Publication number: 20030096254
    Abstract: Oligonucleotide probes containing two labels are provided and are useful in hybridization assays. The probes can also contain a minor groove binding group.
    Type: Application
    Filed: March 29, 2002
    Publication date: May 22, 2003
    Applicant: Epoch Biosciences, Inc.
    Inventors: Michael W. Reed, Eugeny Alexander Lukhtanov, Alexander A. Gall, Robert O. Dempcy, Nicolaas M.J. Vermeulen
  • Publication number: 20020155606
    Abstract: A target gene can be expressed site-specifically and with desired timing without damaging the cell itself or inducing mutation in a nucleic acid molecule within the cell. Expression of the above target gene is suppressed by allowing a caging agent represented by the following formula (1) to bind to a nucleic acid molecule containing the target gene; and the suppression of expression of the above target gene is cancelled by detaching the caging agent from the above nucleic acid molecule by UV-illumination.
    Type: Application
    Filed: April 22, 2002
    Publication date: October 24, 2002
    Inventors: Hitoshi Okamoto, Hideki Ando, Toshiaki Furuta
  • Publication number: 20020103169
    Abstract: Novel anticancer agents of the phenanthridine class having a specific mechanism of action and cancer therapy methods are described, including the novel chemical compounds and their therapeutic use thereof in humans.
    Type: Application
    Filed: August 8, 2001
    Publication date: August 1, 2002
    Inventors: Patrick Mailliet, Jean-Francois Riou, Jean-Louis Mergny, Abdelazize Laoui
  • Patent number: 6284220
    Abstract: Nucleic acid-imaging compositions and methods for noninvasive imaging of a nucleic acid introduced into somatic tissues of an animal or human are disclosed. The noninvasive imaging enables quantitative assessment of the biodistribution of the introduced nucleic acid. The disclosed imaging compounds include a base-binding moiety, a phosphate-binding moiety, and a metal-binding moiety. A chelated metal is non-invasively detected for imaging by radioactivity or magnetic resonance.
    Type: Grant
    Filed: June 3, 1999
    Date of Patent: September 4, 2001
    Assignee: The General Hospital Corporation
    Inventors: Alexei Bogdanov, Ching-Hsuan Tung, Ralph Weissleder